UBS Group’s GRI Bio GRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $36.7K | Buy |
19,029
+14,109
| +287% | +$25.2K | ﹤0.01% | 7901 |
|
|
2026
Q2 | $8.71K | Sell |
4,920
-3,802
| -44% | -$8.42K | ﹤0.01% | 8654 |
|
|
2026
Q1 | $20K | Buy |
+8,722
| New | +$32.5K | ﹤0.01% | 7938 |
|
|
2025
Q4 | – | Sell |
-1
| Closed | -$56 | – | 10771 |
|
|
2025
Q3 | $56 | Sell |
1
-551
| -100% | -$25.5K | ﹤0.01% | 10006 |
|
|
2025
Q2 | $19.9K | Buy |
552
+436
| +376% | +$18.2K | ﹤0.01% | 8444 |
|
|
2025
Q1 | $10.4K | Sell |
116
-78
| -40% | -$19.6K | ﹤0.01% | 8631 |
|
|
2024
Q4 | $76.4K | Buy |
194
+43
| +28% | +$14.7K | ﹤0.01% | 7041 |
|
|
2024
Q3 | $25.9K | Buy |
151
+113
| +297% | +$45.5K | ﹤0.01% | 7211 |
|
|
2024
Q2 | $34.5K | Buy |
38
+37
| +3,700% | +$88.1K | ﹤0.01% | 6974 |
|
|
2024
Q1 | $6.1K | Buy |
+1
| New | +$8.53K | ﹤0.01% | 7483 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 8474 |
|
|
2023
Q3 | – | Hold |
0
| – | -$3.82K | – | 9648 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 7598 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 8825 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 9117 |
|
|
2022
Q2 | – | Hold |
0
| – | -$17K | – | 10553 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 7649 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 8064 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 7879 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 8665 |
|
Other funds holding GRI
UBS Group's GRI Position: Q3 2026 in Review
UBS Group increased its GRI Bio (GRI) stake by 287% in Q3 2026, buying an estimated $25.2K and bringing the position to 19,029 shares worth $36.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7901.
UBS Group first reported a position in GRI in Q1 2024 and has held it in 10 quarters since. The position peaked at $76.4K in Q4 2024. 5 funds tracked by Wall St. Rank hold GRI as of Q3 2026.
- UBS Group held 19,029 shares of GRI Bio worth $36.7K as of Q3 2026.
- UBS Group bought 14,109 GRI Bio shares in Q3 2026, an estimated $25.2K.
- GRI Bio made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #7901 holding.
- UBS Group first reported a position in GRI Bio in Q1 2024 and has held it in 10 quarters since.
- UBS Group's GRI Bio position peaked at $76.4K in Q4 2024.
- 5 funds tracked by Wall St. Rank held GRI Bio as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.